Jardiance Cost in Louisiana 2026: Prices, Coverage, and Cheaper Alternatives

What Is the Actual Price of Jardiance in Louisiana in 2026?

The Boehringer Ingelheim/Lilly wholesale acquisition cost for Jardiance sits at approximately $680 per month for a 30-tablet supply of either the 10 mg or 25 mg dose in 2026. That number is what retail Louisiana pharmacies anchor their cash price to. Across major chains, including CVS, Walgreens, Walmart, and independent Louisiana pharmacies, out-of-pocket cash prices cluster tightly around that $680 figure, with some minor variation based on pharmacy dispensing fees.

Pharmacy benefit managers negotiate rebates behind the scenes, but those rebates flow to insurers, not directly to patients. If you are uninsured or paying cash at the counter, you will see a price very close to the list price unless you use a manufacturer coupon, a third-party discount card, or a patient-assistance program. GoodRx and similar aggregators sometimes show prices as low as $550, $600 at select Louisiana zip codes, but those quotes are inconsistent and pharmacy-specific. The FDA label for Jardiance is publicly available and documents the approved dosing that drives the cost calculation. [1]

Patients with commercial insurance are in a materially different position. Tier placement for Jardiance varies by plan, but most major commercial formularies in Louisiana place it on Tier 3 or Tier 4, producing a pre-coupon copay anywhere from $80 to $200 per 30-day supply before the savings card is applied. [2]

Does Louisiana Medicaid Cover Jardiance?

Louisiana Medicaid does not cover Jardiance as of 2026 for the majority of its approximately 2.3 million enrollees. The Louisiana Department of Health Preferred Drug List (PDL) does not include empagliflozin on its covered formulary for standard fee-for-service Medicaid. [3]

Managed care organizations (MCOs) contracted with Louisiana Medicaid, including Aetna Better Health, Healthy Blue, and UnitedHealthcare Community Plan, each maintain their own drug lists. A small number of MCO plans have added SGLT2 inhibitors for heart failure or CKD indications under prior authorization, but coverage is the exception rather than the rule. Checking your specific MCO's current formulary directly is the only reliable way to confirm your benefit.

For dual-eligible patients covered by both Medicare and Louisiana Medicaid, Medicare Part D governs prescription drug coverage. Most Part D plans include at least one SGLT2 inhibitor, though empagliflozin's tier placement and applicable copay vary. The 2025 Medicare Part D redesign caps annual out-of-pocket drug costs at $2,000, which may reduce net annual cost for Louisiana patients who previously reached catastrophic coverage. [4]

How Does Commercial Insurance Cover Jardiance in Louisiana?

Commercial formulary placement determines your real cost more than the list price does. Louisiana residents covered through employer-sponsored plans, ACA marketplace plans, or individual commercial policies will find Jardiance on most major formularies, albeit at higher tiers.

Blue Cross and Blue Shield of Louisiana, one of the state's largest commercial carriers, generally places Jardiance on Tier 3 of its standard formulary. Humana and United plans operating in Louisiana follow similar tier structures. A Tier 3 copay typically runs $80, $150 per 30-day fill, before any manufacturer discount is applied. [2]

Prior authorization (PA) requirements are common. Insurers typically require documentation of a type 2 diabetes diagnosis confirmed by HbA1c measurement, prior metformin use, or a cardiovascular/CKD indication supported by chart notes and lab values. The American Diabetes Association's 2024 Standards of Care explicitly recommend SGLT2 inhibitors for patients with type 2 diabetes and established cardiovascular disease or CKD, which strengthens the clinical basis for PA approval. [5] Specifically, the ADA states: "For patients with type 2 diabetes and established cardiovascular disease, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events and/or heart failure hospitalization." [5]

Step therapy, requiring documented failure or contraindication to metformin and sometimes one additional oral agent, is required by many Louisiana plans before Jardiance will be approved. Your prescribing clinician can submit a PA with supporting documentation to bypass step therapy when a clinical exception applies.

What Is the Boehringer Ingelheim / Lilly Savings Card and How Does It Work in Louisiana?

The Boehringer Ingelheim/Lilly Jardiance savings card reduces the monthly cost to as low as $10 per month for eligible commercially insured Louisiana patients, and to a maximum of $35 per month under most program terms. The program is available at participating retail pharmacies throughout Louisiana.

Eligibility requires commercial insurance coverage. Patients enrolled in any federal or state government health program, including Louisiana Medicaid, Medicare, TRICARE, or VA benefits, do not qualify by law. [6] The savings card covers the gap between your insurer's negotiated price and the patient copay floor, subject to an annual maximum benefit (historically capped at $3,600, $7,200 per year depending on program year).

Enrollment is available at JardiancePro.com or through your prescribing clinician's office. The card is presented at the pharmacy alongside your insurance card at the time of fill. No income verification is required for the commercial savings card. The card does not work on cash-pay fills; it is a copay offset for insured patients only.

Is Compounded Empagliflozin Legal in Louisiana?

Yes. Compounded empagliflozin prepared by a 503A pharmacy licensed in Louisiana is legal as of 2026. [7] A 503A pharmacy compounds medications for individual patients pursuant to a valid prescription from a licensed prescriber. Louisiana state pharmacy law, administered by the Louisiana Board of Pharmacy, permits 503A compounding of empagliflozin because the FDA has not placed the compound on any list that would restrict its preparation at this tier.

This is a meaningfully different legal status from GLP-1 compounds like semaglutide, which were permissible during the FDA shortage declaration but became restricted once the shortage resolved in early 2025. Empagliflozin does not currently carry a shortage-related compounding restriction, so 503A pharmacies may compound it for patients with a valid prescription regardless of whether the brand product is in shortage. [8]

Cash prices at Louisiana-licensed 503A compounding pharmacies vary, but patients routinely pay significantly less than the $680 brand list price. Exact pricing depends on the compound's dose, base, and the individual pharmacy's cost structure. A telehealth clinician licensed in Louisiana can write the prescription; the compound is then dispensed and may be mailed to a Louisiana address by the compounding pharmacy if that pharmacy holds an active Louisiana non-resident or in-state pharmacy license.

Quality considerations matter. Compounded medications are not FDA-approved, meaning they do not carry the same manufacturing standards as brand Jardiance. Potency, sterility (for non-oral forms), and excipient quality depend entirely on the compounding pharmacy's practices. [9] Patients choosing a compounded product should ask whether the pharmacy is PCAB-accredited (Pharmacy Compounding Accreditation Board), which signals adherence to USP standards.

What Do the Clinical Trials Say About Empagliflozin Efficacy?

Understanding what empagliflozin does clinically helps patients and clinicians evaluate whether the cost is justified for a specific indication. The landmark EMPA-REG OUTCOME trial (N=7,020) published in the New England Journal of Medicine in 2015 showed that empagliflozin 10 mg or 25 mg once daily reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% relative to placebo (hazard ratio 0.86; 95% CI 0.74, 0.99; P<0.001 for noninferiority, P=0.04 for superiority). Cardiovascular death was reduced by 38% in relative terms. [10]

The EMPEROR-Reduced trial (N=3,730) demonstrated that empagliflozin 10 mg daily reduced the composite of cardiovascular death or hospitalization for heart failure by 25% (HR 0.75; 95% CI 0.65, 0.86; P<0.001) in patients with heart failure with reduced ejection fraction, regardless of diabetes status. [11]

The EMPA-KIDNEY trial (N=6,609), published in the New England Journal of Medicine in 2023, extended those findings to chronic kidney disease. Empagliflozin 10 mg daily reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72; 95% CI 0.64, 0.82; P<0.001). [12] These three trials form the evidentiary backbone of the FDA's approvals across three distinct indications. [1]

The FDA label documents starting doses of 10 mg once daily for type 2 diabetes and heart failure, with uptitration to 25 mg permitted in diabetes for additional glycemic benefit. Renal function (eGFR) thresholds govern dosing: empagliflozin is not recommended when eGFR drops below 20 mL/min/1.73m² for diabetes, though the CKD indication extends to lower eGFR ranges as established in EMPA-KIDNEY. [1] [12]

What Risks and Contraindications Should Louisiana Patients Know?

Empagliflozin is not appropriate for everyone. The FDA label lists type 1 diabetes and dialysis as contraindications. [1] Clinically important risks include diabetic ketoacidosis (DKA), which may present with near-normal glucose levels and is more common in patients who are fasting, volume-depleted, or consuming low-carbohydrate diets. [13]

Genital mycotic infections occur in roughly 9% of women and 4% of men taking SGLT2 inhibitors based on pooled trial data. [14] Fournier's gangrene, a rare but severe necrotizing fasciitis of the genitalia and perineum, has been reported with the class and carries an FDA black-box adjacent warning (labeled as a serious warning, not a formal black box). [1] Volume depletion and urinary tract infections occur at modestly higher rates than placebo across trials. [10]

The FDA also flags the risk of lower-limb amputation, particularly for patients with peripheral vascular disease, prior amputation, or active foot ulcers. CANVAS trial data for canagliflozin showed a doubling of amputation risk; EMPA-REG OUTCOME did not demonstrate the same signal for empagliflozin, but the class-level caution remains on the label. [1] [10]

Drug interactions are limited but include diuretics and insulin, both of which increase volume depletion and hypoglycemia risk respectively when combined with empagliflozin. Louisiana patients taking loop diuretics for heart failure should have their volume status reassessed when empagliflozin is added.

Can You Get an Empagliflozin Prescription via Telehealth in Louisiana?

Telehealth prescribing of Jardiance and compounded empagliflozin is legal in Louisiana. A clinician holding an active Louisiana medical, APRN, or PA license may evaluate a patient via synchronous audio-video telehealth and issue a valid prescription for empagliflozin without an in-person visit, provided the clinical evaluation meets standard-of-care requirements. [15]

Louisiana participates in the Interstate Medical Licensure Compact (IMLC), which allows physicians licensed in other compact states to obtain Louisiana licensure more easily, expanding the telehealth clinician pool available to Louisiana patients. [15]

For a telehealth visit to support an empagliflozin prescription, the clinician will typically review your diagnosis (type 2 diabetes, HFrEF, or CKD), recent HbA1c, eGFR, and urine albumin-to-creatinine ratio (UACR), along with a medication and allergy list. Existing lab work obtained within the past 3 to 6 months is usually sufficient. The clinician can send the prescription electronically to a Louisiana retail pharmacy or to a licensed 503A compounding pharmacy, depending on which formulation is appropriate.

HealthRX clinicians licensed in Louisiana conduct these evaluations and can route prescriptions to the pharmacy of your choice. Visits are typically completed within 24 to 48 hours.

What Is the Cheapest Way to Get Empagliflozin in Louisiana?

The lowest realistic monthly cost depends on your insurance status.

Commercially insured patients should use the Boehringer Ingelheim/Lilly savings card alongside their insurance, reducing copay to $10, $35 per month. [6] This is the lowest-cost route for patients with commercial coverage.

Uninsured or cash-pay patients face the $680 brand list price without assistance. For this group, compounded empagliflozin from a licensed Louisiana 503A pharmacy is typically the most accessible low-cost route, with prices that vary by pharmacy but are substantially below brand cost. A telehealth evaluation to obtain the prescription costs a fraction of the brand-drug savings.

Medicare Part D beneficiaries should compare their plan's Explanation of Benefits during Open Enrollment (October 15 through December 7 each year) to identify which plan places SGLT2 inhibitors at the lowest net tier. Some Part D plans include empagliflozin on Tier 2 or Tier 3, and the $2,000 annual cap introduced in 2025 limits catastrophic exposure. [4]

Louisiana Medicaid enrollees who cannot access coverage through their MCO may be eligible for Boehringer Ingelheim's patient assistance program (PAP), which provides free medication to qualifying low-income uninsured patients. Income thresholds and application requirements are managed directly by the manufacturer and do not require a Louisiana Medicaid denial letter, though that documentation strengthens the application. [6]

The following decision framework summarizes the cost pathway by coverage type:

Coverage Status and Recommended Cost Pathway

• Commercial insurance: Apply savings card at pharmacy. Target cost $10, $35/month.
• Medicare Part D: Compare formularies at open enrollment. $2,000 OOP cap applies in 2025+.
• Louisiana Medicaid (fee-for-service): Not covered. Evaluate PAP eligibility or compounded alternative.
• Louisiana Medicaid (MCO): Check individual MCO PDL. PA may reveal coverage for CKD/HF indications.
• Uninsured/cash-pay: Compounded empagliflozin via licensed 503A pharmacy is typically the lowest-cost legal option.
• Medicare + Medicaid dual-eligible: Part D governs; use Part D formulary comparison tool at Medicare.gov.

Monitoring Requirements That Affect Total Cost of Care

Empagliflozin does not operate in isolation. Guideline-concordant care requires baseline and periodic labs that add to overall cost. The ADA 2024 Standards of Care recommend measuring eGFR and UACR at baseline and at least annually in patients with CKD on SGLT2 inhibitors. [5] HbA1c measurement every 3 months is appropriate when glycemic control is being established, dropping to every 6 months once stable. [5]

A basic metabolic panel (BMP) at initiation checks potassium (particularly relevant when combining with ACE inhibitors or ARBs in CKD/HF patients) and establishes baseline renal function. Volume status assessment matters for patients on diuretics. These labs are generally covered by commercial insurance and Medicare with a covered diagnosis code, and Louisiana Medicaid covers standard lab panels under its clinical laboratory benefit even when the associated drug is not covered.

Genital hygiene counseling and instruction on when to hold empagliflozin (before major surgery, during prolonged fasting, or during acute illness) reduces adverse event risk without adding cost. Your prescribing clinician should provide this guidance at the time of prescription.

Patients who develop signs of DKA, including nausea, vomiting, abdominal pain, or malaise, should stop empagliflozin and seek care immediately, regardless of blood glucose readings, because euglycemic DKA can occur with glucose levels below 250 mg/dL. [13]